Myelin oligodendrocyte glycoprotein autoantibodies (MOG-Ab) have been identified in patients with various central nervous system (CNS) demyelinating diseases, including single or recurrent optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), encephalitis, and brainstem encephalitis (1, 2). This evidence concerns the gene MOG and transverse myelitis.